Cidara Therapeutics (CDTX) Competitors $21.75 +0.86 (+4.12%) Closing price 04:00 PM EasternExtended Trading$21.73 -0.02 (-0.09%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX vs. COLL, ZYME, PHVS, SYRE, MLYS, NTLA, NRIX, GYRE, RCUS, and AVDLShould you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Pharvaris (PHVS), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Intellia Therapeutics (NTLA), Nurix Therapeutics (NRIX), Gyre Therapeutics (GYRE), Arcus Biosciences (RCUS), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Cidara Therapeutics vs. Collegium Pharmaceutical Zymeworks Pharvaris Spyre Therapeutics Mineralys Therapeutics Intellia Therapeutics Nurix Therapeutics Gyre Therapeutics Arcus Biosciences Avadel Pharmaceuticals Collegium Pharmaceutical (NASDAQ:COLL) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking. Do analysts rate COLL or CDTX? Collegium Pharmaceutical currently has a consensus target price of $43.60, suggesting a potential upside of 62.42%. Cidara Therapeutics has a consensus target price of $39.14, suggesting a potential upside of 81.55%. Given Cidara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cidara Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has preferable earnings and valuation, COLL or CDTX? Collegium Pharmaceutical has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCollegium Pharmaceutical$631.45M1.37$48.15M$1.8614.43Cidara Therapeutics$1.28M185.21-$22.93M-$30.09-0.72 Does the MarketBeat Community believe in COLL or CDTX? Cidara Therapeutics received 66 more outperform votes than Collegium Pharmaceutical when rated by MarketBeat users. Likewise, 70.31% of users gave Cidara Therapeutics an outperform vote while only 65.49% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformCollegium PharmaceuticalOutperform Votes39165.49% Underperform Votes20634.51% Cidara TherapeuticsOutperform Votes45770.31% Underperform Votes19329.69% Do insiders and institutionals have more ownership in COLL or CDTX? 35.8% of Cidara Therapeutics shares are owned by institutional investors. 2.5% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is COLL or CDTX more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Cidara Therapeutics' net margin of -289.05%. Collegium Pharmaceutical's return on equity of 104.67% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Collegium Pharmaceutical14.78% 104.67% 18.38% Cidara Therapeutics -289.05%-69.64%-33.73% Which has more risk & volatility, COLL or CDTX? Collegium Pharmaceutical has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Does the media favor COLL or CDTX? In the previous week, Cidara Therapeutics had 2 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 8 mentions for Cidara Therapeutics and 6 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.05 beat Cidara Therapeutics' score of 0.88 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cidara Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCidara Therapeutics beats Collegium Pharmaceutical on 11 of the 19 factors compared between the two stocks. Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDTX vs. The Competition Export to ExcelMetricCidara TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$238.63M$2.95B$5.49B$7.94BDividend YieldN/A1.89%5.11%4.23%P/E Ratio-0.8530.1722.5818.55Price / Sales185.21492.83397.25103.00Price / CashN/A168.6838.1834.62Price / Book-11.853.176.704.26Net Income-$22.93M-$72.35M$3.23B$248.39M7 Day Performance0.37%0.65%1.26%1.27%1 Month Performance13.95%7.90%3.75%3.85%1 Year Performance82.56%-22.99%15.78%5.23% Cidara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTXCidara Therapeutics4.2494 of 5 stars$21.75+4.1%$39.14+80.0%+74.4%$238.23M$1.28M-0.8590Upcoming EarningsAnalyst ForecastNews CoverageCOLLCollegium Pharmaceutical4.0398 of 5 stars$26.87+0.3%$43.60+62.3%-26.9%$904.19M$631.45M11.58210Upcoming EarningsPositive NewsZYMEZymeworks2.7664 of 5 stars$12.88+2.5%$21.00+63.0%+51.6%$896.15M$76.30M-8.59460Upcoming EarningsAnalyst RevisionPositive NewsPHVSPharvaris2.0193 of 5 stars$17.06+1.3%$42.67+150.1%-24.8%$892.07MN/A-6.0930Analyst ForecastAnalyst RevisionNews CoveragePositive NewsHigh Trading VolumeSYRESpyre Therapeutics1.9141 of 5 stars$14.67+3.8%$49.57+237.9%-53.9%$884.25M$890,000.00-1.96100Upcoming EarningsNews CoveragePositive NewsMLYSMineralys Therapeutics2.3831 of 5 stars$13.56+1.6%$33.00+143.4%+16.0%$879.72MN/A-3.7328Upcoming EarningsShort Interest ↑NTLAIntellia Therapeutics4.6011 of 5 stars$8.48+2.0%$36.68+332.6%-58.6%$877.82M$57.88M-1.56600Upcoming EarningsPositive NewsGap UpNRIXNurix Therapeutics1.9307 of 5 stars$11.47-0.8%$30.44+165.4%-4.1%$874.43M$56.42M-3.97300Analyst ForecastGYREGyre Therapeutics0.0667 of 5 stars$9.32+2.8%N/A-37.4%$873.69M$105.76M186.4040Upcoming EarningsNews CoverageRCUSArcus Biosciences2.2783 of 5 stars$8.25-0.6%$28.38+243.9%-42.6%$867.39M$258M-2.62500Upcoming EarningsPositive NewsAVDLAvadel Pharmaceuticals2.2389 of 5 stars$8.75-0.2%$19.88+127.1%-51.0%$845.50M$169.12M-11.0870Upcoming EarningsPositive News Related Companies and Tools Related Companies Collegium Pharmaceutical Competitors Zymeworks Competitors Pharvaris Competitors Spyre Therapeutics Competitors Mineralys Therapeutics Competitors Intellia Therapeutics Competitors Nurix Therapeutics Competitors Gyre Therapeutics Competitors Arcus Biosciences Competitors Avadel Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CDTX Stock Free CDTX Stock Alerts